In a recent study, cucurbitacin I (CUI) has been identified as a strong inhibitor of the JAK2/STAT3 signaling pathway (a common oncogenic signaling pathway), which is constitutively activated in many types of cancer; hence, it is considered as a milestone in cancer therapy7. Here, JAK2 is linked to cancer.